{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:28:49Z","timestamp":1773977329796,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2026.116221","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:12:28Z","timestamp":1767802348000},"page":"116221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"235","author":[{"given":"Xinghao","family":"Ai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiakui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2622-6187","authenticated-orcid":false,"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116221_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib3","first-page":"83","article-title":"Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives","volume":"7","author":"Giroux-Leprieur","year":"2016","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.ejca.2026.116221_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ph13120474","article-title":"The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer","volume":"13","author":"Gristina","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejca.2026.116221_bib5","first-page":"94","article-title":"Alectinib and Brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer","volume":"9","author":"Beardslee","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.21037\/tlcr-20-331","article-title":"How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)","volume":"9","author":"Xia","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116221_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2017.03.006","article-title":"The accelerated path of ceritinib: translating pre-clinical development into clinical efficacy","volume":"55","author":"Mok","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116221_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hoc.2016.08.012","article-title":"Diagnosis and treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"31","author":"Arbour","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2026.116221_bib9","article-title":"Targeting ALK rearrangements in NSCLC: current state of the art","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116221_bib11","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110264","article-title":"EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3\/Slug signaling","volume":"92","author":"Shen","year":"2022","journal-title":"Cell Signal"},{"key":"10.1016\/j.ejca.2026.116221_bib14","first-page":"1602","article-title":"Pharmacodynamic study of dirozalkib","volume":"41","author":"JIANG Ben-ke","year":"2025","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2026.116221_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: What does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejca.2026.116221_bib16","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116221_bib17","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.18632\/oncotarget.23840","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116221_bib18","article-title":"Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer","volume":"98","author":"Li","year":"2019","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejca.2026.116221_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116221_bib20","first-page":"163","article-title":"Zykadia (Ceritinib) approved for patients with crizotinib-resistant ALK -positive non-small-cell lung cancer","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ejca.2026.116221_bib21","unstructured":"Instructions for Brigatinib Tablets 2025. Available from: \u3008https:\/\/assets-dam.takeda.com\/image\/upload\/LOC\/zh-cn\/products\/%E5%AE%89%E4%BC%AF%E7%91%9E\/%E5%AE%89%E4%BC%AF%E7%91%9E_%E5%B8%83%E6%A0%BC%E6%9B%BF%E5%B0%BC%E7%89%87_%E8%AF%B4%E6%98%8E%E4%B9%A6_20250404.pdf\u3009."},{"key":"10.1016\/j.ejca.2026.116221_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2026.116221_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-017-3405-3","article-title":"Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC","volume":"17","author":"Zhu","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116221_bib24","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.2147\/CMAR.S190098","article-title":"The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2026.116221_bib25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jcpt.13157","article-title":"Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: a systematic review and meta-analysis","volume":"45","author":"Tian","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2026.116221_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/1471-2407-14-683","article-title":"The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials","volume":"14","author":"Qian","year":"2014","journal-title":"BMC Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:22:25Z","timestamp":1773973345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"alternative-id":["S0959804926000018"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116221","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116221"}}